Published in J Clin Hypertens (Greenwich) on October 01, 2008
Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines. J Clin Hypertens (Greenwich) (2012) 0.95
Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens (2011) 0.89
How does prescribing for antihypertensive products stack up against guideline recommendations? An Australian population-based study (2006-2014). Br J Clin Pharmacol (2016) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Genome-wide association study of 107 phenotypes in Arabidopsis thaliana inbred lines. Nature (2010) 10.66
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med (2002) 5.80
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 3.89
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA (2004) 3.88
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation (2006) 3.69
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med (2006) 3.64
Lost in translation: challenges and opportunities in physician-to-physician communication during patient handoffs. Acad Med (2005) 3.30
The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med (2006) 2.97
Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med (2013) 2.74
Racial differences in the prevalence of atrial fibrillation among males. J Natl Med Assoc (2008) 2.58
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation (2004) 2.56
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation (2008) 2.51
Identifying hypertension-related comorbidities from administrative data: what's the optimal approach? Am J Med Qual (2004) 2.47
Disparities in diabetes care: impact of mental illness. Arch Intern Med (2005) 2.45
Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med (2015) 2.42
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Self-reported vs administrative race/ethnicity data and study results. Am J Public Health (2002) 2.32
Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One (2011) 2.24
Exercise capacity and mortality in black and white men. Circulation (2008) 2.17
Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. J Hypertens (2010) 2.14
Diabetes and hypertension: the bad companions. Lancet (2012) 2.10
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension (2008) 2.10
Pharmacy benefits management in the Veterans Health Administration: 1995 to 2003. Am J Manag Care (2005) 2.08
Effects of continuous positive airway pressure on blood pressure in hypertensive patients with obstructive sleep apnea: a 3-year follow-up. J Hypertens (2013) 2.03
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med (2005) 1.99
Blood pressure and survival in the oldest old. J Am Geriatr Soc (2007) 1.98
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int (2011) 1.91
Ascertainment of Testosterone Prescribing Practices in the VA. Med Care (2015) 1.89
Do age and comorbidity affect intensity of pharmacological therapy for poorly controlled diabetes mellitus? J Am Geriatr Soc (2005) 1.78
Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J (2013) 1.77
Clinical relevance of automated drug alerts from the perspective of medical providers. Am J Med Qual (2005) 1.73
Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care (2013) 1.71
Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg (2010) 1.70
Hypertensive patients' race, health beliefs, process of care, and medication adherence. J Gen Intern Med (2007) 1.69
Measuring the quality of depression care in a large integrated health system. Med Care (2003) 1.69
Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens (2002) 1.69
Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study. J Hypertens (2003) 1.69
Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med (2010) 1.64
Systematic review: comparison of the quality of medical care in Veterans Affairs and non-Veterans Affairs settings. Med Care (2011) 1.63
Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study. J Hypertens (2009) 1.62
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes (2012) 1.59
How do providers assess antihypertensive medication adherence in medical encounters? J Gen Intern Med (2006) 1.58
Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med (2010) 1.57
Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care (2012) 1.55
Using administrative data to identify mental illness: what approach is best? Am J Med Qual (2009) 1.54
Exercise capacity and mortality in older men: a 20-year follow-up study. Circulation (2010) 1.54
Hypertension control: how well are we doing? Arch Intern Med (2003) 1.53
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes (2010) 1.50
Adverse outcomes associated with inappropriate drug use in nursing homes. Ann Pharmacother (2005) 1.50
Comparisons of quality of surgical care between the US Department of Veterans Affairs and the private sector. J Am Coll Surg (2010) 1.47
Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension (2008) 1.46
Perceptions of standards-based electronic prescribing systems as implemented in outpatient primary care: a physician survey. J Am Med Inform Assoc (2009) 1.45
Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic Res Cardiol (2008) 1.44
Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hypertens (2008) 1.44
Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. J Clin Hypertens (Greenwich) (2013) 1.44
Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD. Am J Kidney Dis (2012) 1.44
Patient safety in geriatrics: a call for action. J Gerontol A Biol Sci Med Sci (2003) 1.43
Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans. Am J Nephrol (2015) 1.42
Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin. Thromb Haemost (2015) 1.42
Aspirin under fire: aspirin use in the primary prevention of coronary heart disease. Pharmacotherapy (2005) 1.41
Follow-up study of a pharmacovigilance signal: no evidence of increased risk with risperidone of pituitary tumor with mass effect. J Clin Psychopharmacol (2012) 1.41
Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache (2004) 1.39
Hypertension and heart failure. Roundtable discussion. J Clin Hypertens (Greenwich) (2004) 1.38
Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2. Am J Physiol Heart Circ Physiol (2005) 1.37
Assessing potentially inappropriate prescribing in the elderly Veterans Affairs population using the HEDIS 2006 quality measure. J Manag Care Pharm (2006) 1.35
Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm (2003) 1.34
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. Am Heart J (2007) 1.33
Barriers to hypertension control. Am Heart J (2005) 1.32
PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res (2003) 1.29
Prehypertension, racial prevalence and its association with risk factors: Analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Am J Hypertens (2010) 1.28
Understanding uncontrolled hypertension: is it the patient or the provider? J Clin Hypertens (Greenwich) (2007) 1.27
Association mapping with single-feature polymorphisms. Genetics (2006) 1.25
Intensifying therapy for hypertension despite suboptimal adherence. Hypertension (2009) 1.22
Nursing home assessment of cognitive impairment: development and testing of a brief instrument of mental status. J Am Geriatr Soc (2008) 1.21
Racial/ethnic differences in diabetes care for older veterans: accounting for dual health system use changes conclusions. Med Care (2006) 1.20